Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro(IRCCS Humanitas Research Hospital), Camillo Porta(University of Pavia), Monica Lencioni(Azienda Ospedaliera Universitaria Pisana), Reinhard von Roemeling(Daiichi Sankyo (United States)), Guido Gerken, Jean‐Luc Van Laethem(Deventer Ziekenhuis), Antonio Gasbarrini(Università Cattolica del Sacro Cuore), Stefania Salvagni(Ospedale di Parma), Maria Lamar(Arqule (United States)), C. Boni(Ospedale Santa Maria), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Brian Schwartz(Cyclacel Pharmaceuticals (United Kingdom)), Yinpu Chen(Arqule (United States)), Hans Van Vlierberghe(Ghent University Hospital), Morris Sherman(University Health Network), Nicola Personeni(IRCCS Humanitas Research Hospital), Bruno Daniele(Azienda Ospedaliera G.Rummo), Lorenza Rimassa(Humanitas University), Steven A. Miles(Cedars-Sinai Medical Center), Peter Buggisch(Institute for Interdisciplinary Medicine), Luca Cicalese(The University of Texas Medical Branch at Galveston), Giovanni Abbadessa(Morristown Medical Center), Roland M. Schmid(Tumkur University), Jörg Trojan(Goethe University Frankfurt), Ziad Hassoun(Cliniques Universitaires Saint-Luc), Ivan Borbath, Alan Weiss(Vancouver General Hospital), Frank T. Kolligs(Helios Hospital Berlin-Buch)
Cited by 550
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k